N. Niederle
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 42
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 28
- Oncology top 1%
- Lung Cancer Research Studies 25
- Hematology top 1%
- Chronic Myeloid Leukemia Treatments 40
- Hepatology top 2%
-
- Neuroendocrine Tumor Research Advances 20
-
- Lung Cancer Treatments and Mutations 19
-
- Eosinophilic Disorders and Syndromes 18
-
- Testicular diseases and treatments 15
N. Niederle
153 papers receiving 4.1k citations
Hit Papers
Peers
Comparison fields: 5 of 107
- Genetics 1.3k
- Pathology and Forensic Medicine 1.8k
- Oncology 2.2k
- Hematology 698
- Hepatology 298
Countries citing papers authored by N. Niederle
This map shows the geographic impact of N. Niederle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Niederle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Niederle more than expected).
Fields of papers citing papers by N. Niederle
This network shows the impact of papers produced by N. Niederle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Niederle. The network helps show where N. Niederle may publish in the future.
Co-authorship network
The 25 scholars most cited alongside N. Niederle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialbreakdown → | 2013 | 962 |
| 2 | 2008 | 40 | |
| 3 | 2008 | 6 | |
| 4 | 2004 | 6 | |
| 5 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerbreakdown → | 1998 | 786 |
| 6 | 1996 | 7 | |
| 7 | 1995 | 18 | |
| 8 | 1995 | 17 | |
| 9 | 1993 | 51 | |
| 10 | 1992 | 4 | |
| 11 | 1992 | 6 | |
| 12 | 1992 | 1 | |
| 13 | 1992 | 8 | |
| 14 | 1991 | 9 | |
| 15 | 1991 | 5 | |
| 16 | Die Lebensqualität des chronisch Krebskranken | 1990 | 4 |
| 17 | 1990 | 3 | |
| 18 | 1989 | 3 | |
| 19 | 1988 | 5 | |
| 20 | 1987 | 10 |
About N. Niederle
N. Niederle is a scholar working on Genetics, Hematology and Oncology, having authored 161 papers that have together received 4.3k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (42 papers), Chronic Myeloid Leukemia Treatments (40 papers), Lymphoma Diagnosis and Treatment (28 papers), Lung Cancer Research Studies (25 papers), Neuroendocrine Tumor Research Advances (20 papers), Lung Cancer Treatments and Mutations (19 papers), Eosinophilic Disorders and Syndromes (18 papers) and Testicular diseases and treatments (15 papers). The work is most often cited by research in Genetics (1.3k citations), Pathology and Forensic Medicine (1.8k citations) and Oncology (2.2k citations). N. Niederle has collaborated with scholars based in Germany, United States and Austria. Frequent co-authors include S. Seeber, O. Kloke, Mathias Rummel, Wolfram Brugger, Manfred Welslau, Ulrich Kaiser, Eckhart Weidmann, Christina Balser, Axel Hinke and Christoph Losem. Their work appears in journals such as Journal of Clinical Oncology, Blood, Journal of Molecular Medicine, Journal of Cancer Research and Clinical Oncology and Cancer Treatment Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.